Vitamin A Compound Or Derivative Patents (Class 514/725)
-
Patent number: 6849613Abstract: A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q10, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.Type: GrantFiled: August 28, 2002Date of Patent: February 1, 2005Inventors: Kedar N. Prasad, Gerald M. Haase
-
Patent number: 6846494Abstract: A nutritional booster composition suitable for the treatment of pressure ulcers, comprising proteins, carbohydrates and fats and, in a daily unit dose: 3-15 g of arginine or equivalents thereof, 180-840 mg of ascorbic acid equivalents, 50-400 mg of ?-tocopherol equivalents, and 8-40 mg of flavonoids.Type: GrantFiled: May 12, 1999Date of Patent: January 25, 2005Assignee: N.V. NutriciaInventors: Maria Anna Verheul-Koot, Chantal Nelleke Kleijer, Robert Johan Joseph Hageman, Roelof André Bork, Maud Goethals
-
Publication number: 20040265231Abstract: The instant invention provides a method of using antioxidant, e.g., vitamins, as radioprotective agents to mitigate gastrointestinal and hemopoietic toxicity of the radioimmunotherapy., The instant invention further provides a method of combining the administration of antioxidant with BMT to produce an additive radioprotective effect against radiation damage to healthy tissues during the radioimmunotherapy.Type: ApplicationFiled: July 19, 2004Publication date: December 30, 2004Applicant: Center for Molecular Medicine and ImmunologyInventors: Rosalyn D. Blumenthal, David M. Goldenberg
-
Publication number: 20040253332Abstract: A method for regulating the appearance of skin comprising topically applying to said skin a composition comprising: (a) a cosmetically or pharmaceutically acceptable carrier and about 0.05% to about 5% of an extract comprising a low molecular weight hydrolysable tannins, and mixtures thereof; (b) an effective amount of at least one additional skin care active ingredient selected from the group consisting of ant-acne actives, retinoids, ant-cellulite agents, antimicrobial actives, antifungal agents, vitamins, anti-inflamatory agents, tanning agents, allantoin, glucosamine, phytantriol, hydroxyacids, niacinamide, phytosterols, sunscreens and mixtures thereof.Type: ApplicationFiled: March 18, 2004Publication date: December 16, 2004Inventor: Ratan K. Chaudhuri
-
Publication number: 20040241225Abstract: A method for increasing levels of a storage form of a vitamin selected from the group consisting of tocopherol, retinol, vitamin K1 and mixtures thereof in a target tissue of a subject, the method comprising administering to the subject an effective amount of a phosphate derivative of the vitamin so as to cause an accumulation of stored vitamin in the target tissue.Type: ApplicationFiled: February 24, 2004Publication date: December 2, 2004Inventors: Simon Michael West, David Kannar
-
Publication number: 20040235950Abstract: Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of the matrix degrading enzymes and (ii) a cytokine inhibitor that alleviates inflammation and thus also alleviate neutrophil infiltration. Alleviating the matrix degradation and renormalizing procollagen biosynthesis allows for reduced inflammation and better natural repair of acne-affected skin. Inhibiting cytokines alleviates induction of MMPs in resident skin cells, and also alleviates inflammation with its concommitant induction of neutrophils from the blood stream bringing MMPs and elastase into the acne lesion.Type: ApplicationFiled: May 9, 2001Publication date: November 25, 2004Inventors: John J. Voorhees, Sewon Kang, Gary J. Fisher
-
Patent number: 6821510Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.Type: GrantFiled: May 30, 2002Date of Patent: November 23, 2004Assignee: Maxim Pharmaceuticals, Inc.Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
-
Publication number: 20040229849Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.Type: ApplicationFiled: February 12, 2004Publication date: November 18, 2004Inventors: Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Jason Fong, Benjamin A. Auspitz, M. James Nichols, Curtis Keith, Grant R. Zimmermann, Bradley B. Brasher, Noah Sachs, Todd W. Chappell
-
Patent number: 6814983Abstract: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.Type: GrantFiled: December 10, 2002Date of Patent: November 9, 2004Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Publication number: 20040220153Abstract: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.Type: ApplicationFiled: September 24, 2003Publication date: November 4, 2004Inventors: Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Jason Fong, Benjamin A. Auspitz, M. James Nichols, Curtis Keith, Grant R. Zimmermann, Bradley B. Brasher, Noah Sachs, Todd W. Chappell
-
Publication number: 20040198695Abstract: A series of beverages and/or foods, which have protecting and enhancing effects on human's joints and bones and can therefore prevent and treat osteoarthritis, is provided. The beverages and/or foods comprise one or more cartilage- and synovial fluid-enhancing active ingredients or combinations of these ingredients with bone-enhancing calcium and phosphorus additives. Active ingredients in these beverages and/or foods are taken in liquid forms. So they can be easily absorbed and utilized thoroughly by human body.Type: ApplicationFiled: March 5, 2004Publication date: October 7, 2004Inventors: Anhu Li, Qingren Xu
-
Publication number: 20040197283Abstract: Cosmetic/pharmaceutical compositions for promoting hair growth and/or retarding hair loss, and/or for increasing the mean diameter of strands of hair and/or decreasing the heterogeneity thereof, and/or for increasing hair density, and/or for improving the quality and/or the appearance of a head of hair, and/or for inducing repigmentation of the hair, contain thus effective amounts of intimate admixture of vitamin A, vitamin C, vitamin E, and zinc and selenium values.Type: ApplicationFiled: April 19, 2004Publication date: October 7, 2004Applicant: L'OREALInventors: Olivier De La Charriere, Francis Pruche
-
Publication number: 20040198752Abstract: Erb inhibitors used in combination with retinoids are effective to prevent skin injury otherwise caused by retinoids alone.Type: ApplicationFiled: April 14, 2004Publication date: October 7, 2004Inventors: James T. Elder, James Varani
-
Patent number: 6794416Abstract: The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema. More generally, the invention encompasses the use of 13-cis-retinoic acid to treat or prevent certain chronic obstructive airway disorders, particularly chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in mammals, especially humans that smoke or smoked cigarettes. In another aspect, the present invention encompasses the use of pharmaceutical compositions of 13-cis-retinoic acid to treat emphysema. Moreover, the current invention encompasses the use of electrohydrodynamic aerosol devices, aerosol devices and nebulizers to deliver formulations of 13-cis-retinoic acid into the lung of a mammal suffering from emphysema. The invention also encompasses the systemic use as well as the local use of 13-cis-retinoic acid.Type: GrantFiled: September 26, 2001Date of Patent: September 21, 2004Assignee: Syntex (U.S.A.) LLCInventor: Paula N Belloni
-
Patent number: 6790440Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.Type: GrantFiled: May 30, 2002Date of Patent: September 14, 2004Assignee: Maxim Pharmaceuticals, Inc.Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
-
Publication number: 20040176337Abstract: This invention relates to topical compositions of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compositions, or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroid/non-steroid anti-inflammatory agent, to processes for preparation of the compositions, to use of the compositions in preparation of a medicament, and to a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation.Type: ApplicationFiled: December 31, 2003Publication date: September 9, 2004Applicant: WOCKHARDT LIMITEDInventors: Dilip G. Saoji, Rajendra N. Nagori, Milind C. Shukla, Sachin Bhagwat, Shrikant V. Gupte, Mahesh V. Patel, Rasendrakumar Jha, Anil Kukreja, Noel J. De Souza
-
Publication number: 20040170667Abstract: There are disclosed in this specification a useful medicament for therapy and/or prevention of failure of accommodation and food and drink having an improving effect against failure of accommodation.Type: ApplicationFiled: November 12, 2003Publication date: September 2, 2004Inventors: Seiji Hayasaka, Yasunori Nagaki, Takatoshi Uonomi, Mari Sanda
-
Publication number: 20040162269Abstract: This invention relates to the composition and method of treating arthritis, repairing of articular joint surfaces and the relief of symptoms associated with arthritis. The composition comprises a nitric oxide synthase inhibitor and amino sugars. The nitric oxide synthase inhibitor reduces the level of nitric oxide, the free radical believed responsible for the degradation of articular cartilage. Amino sugars are the building blocks of articular cartilage and have anti-inflammatory actions.Type: ApplicationFiled: February 5, 2002Publication date: August 19, 2004Inventor: Edward J. Petrus
-
Patent number: 6773708Abstract: The use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient is disclosed. Excessive Th1 cell mediated immune responses are caused by such autoimmune diseases and chronic viral and intracellular bacterial infections as Psoriasis vulgaris, Multiple sclerosis (MS), Rheumatoid arthritis, Crohn's disease, insulin-dependent diabetes mellitus, Tuberculosis (TB), Acute graft-versus-host disease (transplant rejection) and HIV virus infection. The preferred type of xanthophyll is astaxanthin, particularly in a form esterified with fatty acids, obtainable by for example culturing the algae Haematococcus sp.Type: GrantFiled: March 28, 2002Date of Patent: August 10, 2004Assignee: AstaReal ABInventors: Åke Lignell, Per Böttiger
-
Patent number: 6774111Abstract: The two carbohydrate mixture of this invention utilizes a source of fructose in combination with at least one readily digestible glucose polymer source. The addition of the fructose significantly decreases the glycemic response when compared to the digestible glucose polymer alone. Additional components may be added to the simple two component carbohydrate mixture to form a carbohydrate system suitable for incorporation into an enteral nutritional. This carbohydrate system optionally incorporates nonabsorbent carbohydrates, dietary fiber and indigestible oligosaccharides. The present invention is also directed to an enteral nutritional which incorporates the two component carbohydrate mixture and less than 37% of calories from fat. Additionally, the invention is directed to a method of delivering nutrients to a person with diabetes by feeding the enteral nutritional.Type: GrantFiled: March 14, 2000Date of Patent: August 10, 2004Assignee: Abbott LaboratoriesInventors: Bryan W. Wolf, Bradley A. Zinker, Keith A. Garleb, Joseph E. Walton
-
Patent number: 6770663Abstract: Provided is a method of treating or ameliorating a number of indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I or IA, wherein J is oxygen, sulfur, or N—Rd.Type: GrantFiled: May 19, 2003Date of Patent: August 3, 2004Assignee: Alteon, Inc.Inventors: Dilip Wagle, Martin Gall, Stanley C. Bell, Edmond J. LaVoie
-
Publication number: 20040136938Abstract: The present invention relates to a new cosmetic or pharmaceutical composition charactrized in that it comprises at least on vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen form the group consisting of fucose, polysacharides and oligosaccharides that contain fucose, sisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one acceptable excipient. This composition enables one to reduces significantly, by means of a real synergy effect, the toxic effect of the vitamin component and, therefore, to use in the composition contents of the vitamin component higher or equal to the contents of the products that already exist on the market without any risk for the user.Type: ApplicationFiled: October 20, 2003Publication date: July 15, 2004Inventors: Robert Ladislas, Alexandre Michel Robert, Catherine Sylvie Robert, Jean-Luc Gesztesi
-
Publication number: 20040131710Abstract: This invention relates to methods and compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or intrinsic aging. More particularly, this invention relates to compositions containing certain natural extracts and natural or synthetic retinoids.Type: ApplicationFiled: September 10, 2003Publication date: July 8, 2004Inventors: Miri Seiberg, Jue-Chen Liu, Violetta Iotsova
-
Patent number: 6759436Abstract: A clear aqueous formulation for topical application in the oral cavity of humans to treat leukoplakia contains water, &bgr;-carotene, a water miscible polyol, an unsaturated fatty acid ester, and a surfactant, preferably polyethoxylated castor oil. The formulation preferably also contains a pharmaceutically acceptable anti-oxidant, preferably d-alpha-tocopherol (vitamin E), and is in the form of an oral rinse or as a gel well suited for spreading on gums or other parts of the oral cavity. The formulation is applied in a gel form on a substantially regular daily basis to areas in the oral cavity where leukoplakia lesions are present. Persistent application of the gel results in substantial diminution or total elimination of the leukoplakia lesions.Type: GrantFiled: February 1, 2002Date of Patent: July 6, 2004Assignee: Micelle Products, Inc.Inventors: Wenjie Li, Edward Alosio, David A. Rutolo, Jr., Bricini Faith (Bim) Dema-Ala
-
Patent number: 6756360Abstract: Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.Type: GrantFiled: December 22, 1999Date of Patent: June 29, 2004Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, Paul D. van Poelje
-
Publication number: 20040122110Abstract: The present invention is directed, inter alia, to compositions and methods for treating, healing, or regeneration of ciliated epithelial structures, particularly those of mucosal membranes. In particular, the invention is directed to a method comprising topical administration of vitamin A (including retinoic acid) to ciliated epithelia structures, including, for example, the paranasal sinus mucosa, middle ear epithelium, and tracheal epithelium. In preferred embodiments the inventive methods are used in the context of surgery, and post-surgical healing and regeneration of epithelial and mucosal epithelial structures and cells.Type: ApplicationFiled: September 8, 2003Publication date: June 24, 2004Inventors: Mendy S. MacCabee, Peter H. Hwang, Dennis R. Trune
-
Publication number: 20040115257Abstract: A capsule system for oral delivery of an active agent having low aqueous solubility generally includes, in combination with the active agent, a vehicle for preventing initial active agent dissolution within the gastrointestinal tract and an emulsifier for promoting self-emulsification of the active agent and vehicle in the gastrointestinal tract. A capsule shell is provided for encapsulating the active agent, vehicle and emulsifier with the shell being formulated to open upon ingestion into the gastrointestinal tract and release the active agent and vehicle.Type: ApplicationFiled: November 21, 2003Publication date: June 17, 2004Inventors: Bruce A. Firestone, Thao T. Tran
-
Publication number: 20040106673Abstract: The present invention includes compositions and methods for treatment of prostate cancer which involve the use of 12-O-tetradecanoylphorbol-13-acetate combined with a retinoid such as all-trans-retinoic acid or paclitaxol, wherein the drugs are administered together, and further wherein the combined use of these agents results in a synergistic effect on prostate tumor cell growth.Type: ApplicationFiled: September 8, 2003Publication date: June 3, 2004Inventor: Allan H. Conney
-
Patent number: 6743437Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.Type: GrantFiled: March 24, 2003Date of Patent: June 1, 2004Assignee: Allergan, Inc.Inventors: Orest Olejnik, Patrick M. Hughes, John S. Kent
-
Patent number: 6743433Abstract: Acne is treated or prevented by the topical application of compositions containing an alkanolamine such as dimethylaminoethanol, tyrosine, and a sulfur ingredient such as lipoic acid or glutathione. Adjunct ingredients such as fatty acid esters of ascorbic acid, e.g., ascorbyl palmitate and &agr;-hydroxy acids may be included in the formulations. Compositions of the invention may be used alone, or, in many preferable embodiments, in combination with conventional acne medications such as anti-acne products containing salicylic acid, benzoyl peroxide, or a retinoid. In these embodiments, alkanolamine compositions of the invention are applied to affected skin areas first, and then a conventional acne medication is applied. This maximizes the efficacy of the treatment while minimizing skin irritation caused by conventional medications.Type: GrantFiled: February 27, 2002Date of Patent: June 1, 2004Inventor: Nicholas V. Perricone
-
Patent number: 6740676Abstract: Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.Type: GrantFiled: March 19, 2002Date of Patent: May 25, 2004Assignee: Allergan, Inc.Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha S. Chandraratna
-
Publication number: 20040091557Abstract: Flexible elastomer articles and methods of making the same are disclosed in which a material, a botanical extract, is incorporated into an elastomer emulsion, solution and/or plastisol in order to enhance the physical and therapeutic properties of articles made from these materials. In another aspect, the invention relates to coating surfaces of flexible elastomer articles with a non-Aloe vera mucinous botanical or laboratory produced polysaccharide which is fortified by additives known to protect, restore and moisturize mammalian skin or mucosa and to enhance ease of application or donnability of the article. Flexible elastomer articles include gloves and other single layer or multi-layer flexible elastomer articles.Type: ApplicationFiled: February 25, 2003Publication date: May 13, 2004Inventor: Curtis P. Hamann
-
Publication number: 20040082536Abstract: This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.Type: ApplicationFiled: October 25, 2002Publication date: April 29, 2004Inventors: Kenneth H. Cooper, Ishwarlal Jialal, Scott Montgomery Grundy, Walter Churchill Willett, Jacob Selhub
-
Publication number: 20040077721Abstract: vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.Type: ApplicationFiled: September 5, 2003Publication date: April 22, 2004Inventors: Yang-Dar Yuan, Jayasree Vasudevan, Scott Thacher, Roshantha A. Chandraratna
-
Publication number: 20040071753Abstract: The development and growth of oviparous species such as birds is enhanced by in ovo administration of an enteric modulator such as HMB. The enteric modulator is administered into the amnion, where it is then orally ingested by the subject. The enteric modulator enhances the enteric development of the subject prior to hatch, and enhances the growth of the animal before and after hatch.Type: ApplicationFiled: June 30, 2003Publication date: April 15, 2004Applicants: North Carolina State University, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Zehava Uni, Peter R. Ferket
-
Publication number: 20040068009Abstract: Disclosed herein are systemic formulations comprising beta-carotene and derivatives thereof and a solubilizer selected from tetrahydrofuran (THF), polyethylene glycol (PEG), and mixtures thereof. Generally, the formulations are administered to animals in need thereof in therapeutically effective amounts of beta-carotene and derivatives thereof for the purpose intended. The solubilizers greatly enhance the bioavailability of beta-carotene administered systemically. Another embodiment of the present invention is a method for administering beta-carotene and derivatives thereof to an animal in need thereof by administering the formulation of the present invention. Yet another embodiment is a method for treating an animal in need thereof by administering a therapeutically effective amount of the formulation of the present invention.Type: ApplicationFiled: August 21, 2003Publication date: April 8, 2004Inventor: Steven A. Baranowitz
-
Publication number: 20040062821Abstract: Therapeutic anti-fatigue compositions for administration to a subject including an active combination of a compound of magnesium and sulfur such as magnesium thiosulfate and a mixture of vitamins including A, B6, B12 and D. The combination is present in the composition in an amount sufficient to treat the symptoms of fatigue in a subject. Methods of using such compositions for treating or managing fatigue are also encompassed by the invention.Type: ApplicationFiled: October 1, 2002Publication date: April 1, 2004Inventor: Elena Avram
-
Publication number: 20040063787Abstract: The invention provides compositions and methods for increasing the secretion of mucus within the reproductive tract of a female mammal.Type: ApplicationFiled: September 19, 2002Publication date: April 1, 2004Inventor: Julie M. Villanueva
-
Publication number: 20040057980Abstract: A procedure for the manufacture of contact lenses for eye treatment, eye protection and eye-care wherein the lenses are impregnated with a suitable composition, a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, and a kit containing such a composition and one or more contact lenses are disclosed herein. A method for the treatment and/or car and/or protection of the eye comprising wearing contact lenses impregnated with a suitable composition and a composition for disinfection and/or conservation of eye care products is also disclosed herein.Type: ApplicationFiled: July 8, 2003Publication date: March 25, 2004Inventor: Louis Johan Wagenaar
-
Patent number: 6709663Abstract: A topical delivery composition which employs a multivesicular emulsion in combination with a pharmaceutically/pharmacologically active agent is disclosed. The multivesicular emulsion is formed from a quaternary amine salt emulsifier such as behentrimonium methosulfate. The emulsion is multi-lamellar which is a series of concentric spheres or vesiculars of oil and water phase that can be seen microscopically. As a result, the active is time released over a sustained period rather than spike released as is common with most topicals.Type: GrantFiled: August 31, 2001Date of Patent: March 23, 2004Assignee: HealthPoint, Ltd.Inventor: Robert Espinoza
-
Patent number: 6710083Abstract: A method of treating palmar and plantar fibromatosis is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a patient of an initial dosage of a composition comprising 13-cis-retinoic acid for an initial treatment period, and thereafter administering a maintenance dosage of the composition.Type: GrantFiled: July 9, 2002Date of Patent: March 23, 2004Inventor: L. Dean Parks
-
Patent number: 6699911Abstract: A process is provided for the preparation of cyclohexene derivatives of general formula I or II: in which the substituents R1 and R2 independently of one another are defined as follows: R1 is R2 is OH or a protective group convertible to a hydroxyl group by hydrolysis; R3 and R4 are hydrogen or C1-C4-alkyl; and R5 is hydrogen or C1-C4-acyl, by the reduction of alkyne compounds of general formula III or IV: in which the substituents R1 and X are as defined above, wherein the reducing agent used is a mixture of zinc and at least one compound B selected from the group consisting of ammonium salts, copper salts and alkali metal and alkaline earth metal salts.Type: GrantFiled: September 18, 2001Date of Patent: March 2, 2004Assignee: BASF AktiengesellschaftInventors: Johannes Grimmer, Thomas Müller, Hansgeorg Ernst
-
Patent number: 6696483Abstract: The invention provides pharmaceutical formulations and methods for the treatment of individuals suffering from a condition, disease, or disorder that is treatable by the inhibition of angiogenesis. The compositions comprise a Golgi apparatus disturbing agent in a substantially nontoxic amount effective to inhibit angiogenesis in a patient in need of anti-angiogenesis therapy, a solvent, and a pharmaceutically acceptable carrier. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A.Type: GrantFiled: October 3, 2001Date of Patent: February 24, 2004Assignee: OncoPharmaceutical, Inc.Inventor: Saira Sayed Singh
-
Patent number: 6696083Abstract: The efficacy of vitamins and other nutritional agents in treating and preventing various disease states is improved by administering therapeutically effective levels of these agents on a substantially continuous, 24-hour basis. The concentration of lipid peroxides formed by the autoxidation of lipids, and the concentration of oxygen free radicals, are reduced by continuously administering antioxidant agents. The regeneration of nerve tissue is improved by continuously administering at least one pharmaceutically-acceptable B complex vitamin.Type: GrantFiled: January 30, 1998Date of Patent: February 24, 2004Assignee: DrugTech CorporationInventors: George N. Paradissis, R. Saul Levinson, Mitchell I. Kirschner, Marc S. Hermelin
-
Patent number: 6696069Abstract: Cosmetic skin care methods and compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof. The inventive compositions provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, prevent shine and stickiness, while also providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photoaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin.Type: GrantFiled: June 1, 2001Date of Patent: February 24, 2004Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: Bijan Steven Harichian, Laurence Boen, John Steven Bajor
-
Publication number: 20040034098Abstract: Chronological aging of human skin can be delayed with the topical application of an MMP inhibitor, preferably a retinoid (an indirect MMP inhbitor); retinoids also normalize procollagen biosynthesis. Chronological aging, or natural aging, is evidenced in elderly (80+ years old) skin by increased MMP levels and decreased procollagen levels when compared with younger individuals. Prophylactic treatment of not yet chronologically-aged skin with a retinoid both inhibits degradation of dermal collagen and restores procollagen synthesis. Biopsied sections from elderly skin show that a single treatment of chronologically-aged skin with a retinoid can increase epidermal thickness, improve the dermal collagen density, and promote the formation of rete pegs and dermal papillae. Such benefits are helpful in preventing bruising, tearing, and ulceration of elderly skin. Accordingly, prophylactic treatment begun much earlier in life with an MMP inhibitor and/or a retinoid delays the onset of such symptoms.Type: ApplicationFiled: June 10, 2003Publication date: February 19, 2004Inventors: James Varani, Gary J. Fisher, John J. Voorhees, Sewon Kang
-
Patent number: 6693129Abstract: The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.Type: GrantFiled: October 3, 2001Date of Patent: February 17, 2004Inventor: Matthias Rath
-
Patent number: 6689774Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.Type: GrantFiled: July 26, 2002Date of Patent: February 10, 2004Assignee: Zinc Therapeutics, Canada Inc.Inventor: Henry Fliss
-
Patent number: 6683069Abstract: Exposure of human skin to ultraviolet (UV) radiation from the sun not only induces the production of enzymes (matrix metalloproteinases) that degrade collagen, but also inhibits the synthesis of new collagen by inhibiting the synthesis of procollagen. This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to its exposure to UV radiation.Type: GrantFiled: April 2, 1999Date of Patent: January 27, 2004Assignee: Regents of the University of MichiganInventors: Gary J. Fisher, John J. Voorhees
-
Publication number: 20040013743Abstract: The present invention relates to dietary supplements containing low doses of phytoestrogens for supplementing the specific phytochemical dietary needs of perimenopausal and menopausal women.Type: ApplicationFiled: June 23, 2003Publication date: January 22, 2004Inventor: Sherry D. Jackson